Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1991-5-10
|
| pubmed:abstractText |
Twenty-nine patients with biopsy-confirmed metastatic melanoma (17) or metastatic renal cell carcinoma (12) were treated with escalating doses or recombinant human interleukin-2 (IL-2) administered as weekly 24-h intravenous infusions. Patients received from 3 to 12 x 10(6) C.U./m2 (18-72 x 10(6) I.U./m2) weekly over a treatment period of 1 to 16 weeks, with a median of eight weekly cycles administered. Patients in all treatment groups experienced non-life-threatening systemic side effects consisting of fever, nausea, vomiting, fluid retention, and diarrhea. Grade III hypotension was seen in four of six patients (67%) at 12 x 10(6) C.U./m2, and represented the dose-limiting toxicity. Grade IV hypotension occurred in 1 of 14 patients at 6 x 10(6) C.U./m2; no other grade IV toxicities were observed. Grade III fever occurred in 3 of 11 patients (27%) treated at 3 x 10(6) C.U./m2, 3 of 14 patients (21%) at 6 x 10(6) C.U./m2, and 3 of 6 patients (50%) at 9 x 10(6) C.U./m2. An objective response was observed in 3 of 28 evaluable patients (10%): 1 complete response and 1 partial response in renal cell cancer, and 1 partial response in a melanoma patient. We conclude that for future studies, the recommended dose of IL-2 given as a weekly 24-h infusion is 9 x 10(6) C.U./m2 and that a low rate of objective tumor response can be obtained in patients with melanoma and renal cell carcinoma using this regimen.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
1053-8550
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
57-62
|
| pubmed:dateRevised |
2008-3-18
|
| pubmed:meshHeading |
pubmed-meshheading:2012799-Adult,
pubmed-meshheading:2012799-Aged,
pubmed-meshheading:2012799-Brain Neoplasms,
pubmed-meshheading:2012799-Carcinoma, Renal Cell,
pubmed-meshheading:2012799-Drug Evaluation,
pubmed-meshheading:2012799-Humans,
pubmed-meshheading:2012799-Interleukin-2,
pubmed-meshheading:2012799-Kidney Neoplasms,
pubmed-meshheading:2012799-Lung Neoplasms,
pubmed-meshheading:2012799-Lymphatic Metastasis,
pubmed-meshheading:2012799-Melanoma,
pubmed-meshheading:2012799-Middle Aged,
pubmed-meshheading:2012799-Neoplasm Metastasis,
pubmed-meshheading:2012799-Recombinant Proteins
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: a phase I study.
|
| pubmed:affiliation |
Hematology/Oncology Section, University of California, Davis.
|
| pubmed:publicationType |
Journal Article
|